Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.

Skorda A, Sklirou AD, Sakellaropoulos T, Gianniou DD, Kastritis E, Terpos E, Tsitsilonis OE, Florea BI, Overkleeft HS, Dimopoulos MA, Alexopoulos LG, Trougakos IP.

J Cell Mol Med. 2019 Sep 30. doi: 10.1111/jcmm.14653. [Epub ahead of print]

2.

In vitro immunodetection of prothymosin alpha in normal and pathological conditions.

Karachaliou CE, Kalbacher H, Voelter W, Tsitsilonis OE, Livaniou E.

Curr Med Chem. 2019 Aug 7. doi: 10.2174/0929867326666190807145212. [Epub ahead of print]

PMID:
31389310
3.

4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.

Fortis SP, Kotsakis A, Le Tourneau C, Tsitsilonis OE, Georgoulias V, Baxevanis CN.

Cancer Immunol Immunother. 2019 Aug;68(8):1391-1400. doi: 10.1007/s00262-019-02364-2. Epub 2019 Jul 15. No abstract available.

PMID:
31309256
4.

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.

Papanagnou ED, Terpos E, Kastritis E, Papassideri IS, Tsitsilonis OE, Dimopoulos MA, Trougakos IP.

Oncotarget. 2018 Apr 3;9(25):17797-17809. doi: 10.18632/oncotarget.24882. eCollection 2018 Apr 3.

5.

Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights.

Cheimonidi C, Samara P, Polychronopoulos P, Tsakiri EN, Nikou T, Myrianthopoulos V, Sakellaropoulos T, Zoumpourlis V, Mikros E, Papassideri I, Argyropoulou A, Halabalaki M, Alexopoulos LG, Skaltsounis AL, Tsitsilonis OE, Aligiannis NN, Trougakos IP.

Redox Biol. 2018 Jun;16:169-178. doi: 10.1016/j.redox.2018.02.015. Epub 2018 Mar 1.

6.

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis.

Kostopoulos IV, Paterakis G, Pavlidis D, Kastritis E, Terpos E, Tsitsilonis OE, Papadhimitriou SI.

Blood Cancer J. 2017 Aug 25;7(8):e597. doi: 10.1038/bcj.2017.77. No abstract available.

7.

Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine.

Goldeck D, Theeten H, Hassouneh F, Oettinger L, Wistuba-Hamprecht K, Cools N, Tsitsilonis OE, Pawelec G.

Vaccine. 2017 Aug 3;35(34):4330-4338. doi: 10.1016/j.vaccine.2017.06.082. Epub 2017 Jul 6.

PMID:
28689651
8.

Prothymosin Alpha: An Alarmin and More...

Samara P, Karachaliou CE, Ioannou K, Papaioannou NE, Voutsas IF, Zikos C, Pirmettis I, Papadopoulos M, Kalbacher H, Livaniou E, Tsitsilonis OE, Voelter W.

Curr Med Chem. 2017;24(17):1747-1760. doi: 10.2174/0929867324666170518110033. Review.

PMID:
28521686
9.

In vivo biodistribution and imaging studies with a 99mTc-radiolabeled derivative of the C-terminus of prothymosin alpha in mice bearing experimentally-induced inflammation.

Karachaliou CE, Triantis C, Liolios C, Palamaris L, Zikos C, Tsitsilonis OE, Kalbacher H, Voelter W, Loudos G, Papadopoulos M, Pirmettis I, Livaniou E.

Eur J Pharm Biopharm. 2017 Apr;113:188-197. doi: 10.1016/j.ejpb.2016.12.028. Epub 2017 Jan 11.

PMID:
28087377
10.

Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Samara P, Ioannou K, Tsitsilonis OE.

Vitam Horm. 2016;102:179-207. doi: 10.1016/bs.vh.2016.04.008. Epub 2016 May 27. Review.

PMID:
27450735
11.

A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.

Samara P, Skopeliti M, Tsiatas ML, Georgaki S, Gouloumis C, Voelter W, Dimopoulos AM, Bamias A, Tsitsilonis OE.

Anticancer Res. 2016 Jul;36(7):3373-82.

PMID:
27354596
12.

Infection risk dictates immunological divergence among populations in a Mediterranean lizard.

Sagonas K, Rota IA, Tsitsilonis OE, Pafilis P, Valakos ED.

J Evol Biol. 2016 Sep;29(9):1680-8. doi: 10.1111/jeb.12903. Epub 2016 Jun 11.

13.

Immune responses of a wall lizard to whole-body exposure to radiofrequency electromagnetic radiation.

Mina D, Sagonas K, Fragopoulou AF, Pafilis P, Skouroliakou A, Margaritis LH, Tsitsilonis OE, Valakos ED.

Int J Radiat Biol. 2016;92(3):162-8. doi: 10.3109/09553002.2016.1135262. Epub 2016 Feb 6.

PMID:
26853383
14.

A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides.

Papaioannou NE, Voutsas IF, Samara P, Tsitsilonis OE.

Cell Immunol. 2016 Apr;302:32-40. doi: 10.1016/j.cellimm.2016.01.004. Epub 2016 Jan 7.

PMID:
26790897
15.

Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils.

Karachaliou CE, Liolios C, Triantis C, Zikos C, Samara P, Tsitsilonis OE, Kalbacher H, Voelter W, Papadopoulos M, Pirmettis I, Livaniou E.

Int J Pharm. 2015;486(1-2):1-12. doi: 10.1016/j.ijpharm.2015.03.031. Epub 2015 Mar 18.

PMID:
25796124
16.

Immunophenotypic analysis reveals heterogeneity and common biologic aspects in monoclonal B-cell lymphocytosis.

Kostopoulos IV, Paterakis G, Papadimitriou K, Pavlidis D, Tsitsilonis OE, Papadhimitriou SI.

Genes Chromosomes Cancer. 2015 Apr;54(4):210-21. doi: 10.1002/gcc.22234. Epub 2014 Dec 23.

PMID:
25533355
17.

ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models.

Ioannou K, Cheng KF, Crichlow GV, Birmpilis AI, Lolis EJ, Tsitsilonis OE, Al-Abed Y.

Int J Oncol. 2014 Oct;45(4):1457-68. doi: 10.3892/ijo.2014.2551. Epub 2014 Jul 22.

18.

The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients.

Koumarianou A, Christodoulou MI, Patapis P, Papadopoulos I, Liakata E, Giagini A, Stavropoulou A, Poulakaki N, Tountas N, Xiros N, Economopoulos T, Pectasides D, Tsitsilonis OE, Pappa V.

Exp Hematol Oncol. 2014 Jan 23;3(1):3. doi: 10.1186/2162-3619-3-3.

19.

Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.

Ioannou K, Derhovanessian E, Tsakiri E, Samara P, Kalbacher H, Voelter W, Trougakos IP, Pawelec G, Tsitsilonis OE.

BMC Immunol. 2013 Sep 22;14:43. doi: 10.1186/1471-2172-14-43.

20.

Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.

Baxevanis CN, Voutsas IF, Tsitsilonis OE.

Immunotherapy. 2013 May;5(5):497-511. doi: 10.2217/imt.13.24. Review.

PMID:
23638745
21.

Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.

Voutsas IF, Pistamaltzian N, Tsiatas ML, Skopeliti M, Katsila T, Mavrothalassiti I, Spyrou S, Dimopoulos MA, Tsitsilonis OE, Bamias A.

Eur J Cancer. 2013 May;49(7):1706-14. doi: 10.1016/j.ejca.2012.11.037. Epub 2012 Dec 28.

PMID:
23276721
22.

Oxidative stress-mediated biomolecular damage and inflammation in tumorigenesis.

Sesti F, Tsitsilonis OE, Kotsinas A, Trougakos IP.

In Vivo. 2012 May-Jun;26(3):395-402. Review.

PMID:
22523291
23.

Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy.

Ioannou K, Samara P, Livaniou E, Derhovanessian E, Tsitsilonis OE.

Cancer Immunol Immunother. 2012 May;61(5):599-614. doi: 10.1007/s00262-012-1222-8. Epub 2012 Feb 26. Review.

PMID:
22366887
24.

Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles.

Christodoulou A, Kostakis IK, Kourafalos V, Pouli N, Marakos P, Trougakos IP, Tsitsilonis OE.

Bioorg Med Chem Lett. 2011 May 15;21(10):3110-2. doi: 10.1016/j.bmcl.2011.03.021. Epub 2011 Mar 11.

PMID:
21444205
25.

Chronic antidepressant treatment exerts sexually dimorphic immunomodulatory effects in an experimental model of major depression: do females lack an advantage?

Pitychoutis PM, Griva E, Ioannou K, Tsitsilonis OE, Papadopoulou-Daifoti Z.

Int J Neuropsychopharmacol. 2009 Oct;12(9):1157-63. doi: 10.1017/S1461145709990502. Epub 2009 Aug 24.

PMID:
19698192
26.

Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo.

Georgaki S, Skopeliti M, Tsiatas M, Nicolaou KA, Ioannou K, Husband A, Bamias A, Dimopoulos MA, Constantinou AI, Tsitsilonis OE.

J Cell Mol Med. 2009 Sep;13(9B):3929-38. doi: 10.1111/j.1582-4934.2009.00695.x. Epub 2009 Feb 11.

27.

Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner.

Skopeliti M, Iconomidou VA, Derhovanessian E, Pawelec G, Voelter W, Kalbacher H, Hamodrakas SJ, Tsitsilonis OE.

Mol Immunol. 2009 Feb;46(5):784-92. doi: 10.1016/j.molimm.2008.09.014. Epub 2008 Oct 30.

PMID:
18976813
28.

Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation.

Skopeliti M, Kratzer U, Altenberend F, Panayotou G, Kalbacher H, Stevanovic S, Voelter W, Tsitsilonis OE.

Proteomics. 2007 Jun;7(11):1814-24.

PMID:
17474146
29.

Combining immunological and molecular data to assess phylogenetic relations of some Greek Podarcis species.

Valakos ED, Kourkouli A, Skopeliti M, Pafilis P, Poulakakis N, Voutsas IF, Lymberakis P, Simou C, Voelter W, Tsitsilonis OE.

Comp Biochem Physiol B Biochem Mol Biol. 2007 May;147(1):1-10. Epub 2007 Feb 21.

PMID:
17347009
30.

The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients.

Skopeliti M, Voutsas IF, Klimentzou P, Tsiatas ML, Beck A, Bamias A, Moraki M, Livaniou E, Neagu M, Voelter W, Tsitsilonis OE.

Cancer Immunol Immunother. 2006 Oct;55(10):1247-57. Epub 2006 Feb 2.

PMID:
16453152
31.

The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.

Tsavaris NB, Katsoulas HL, Kosmas C, Papalambros E, Gouveris P, Papantoniou N, Rokana S, Kosmas N, Skopeliti M, Tsitsilonis OE.

Oncology. 2004;67(5-6):403-10.

PMID:
15713997
32.

Serological detection of hepatitis B viral infection by a panel of solid-phase enzyme-linked immunosorbent assays (ELISA).

Tsitsilonis OE, Thrasyvoulides A, Balafas A, Voutsas JF, Papamichail M, Lymberi P.

J Pharm Biomed Anal. 2004 Mar 1;34(4):811-22.

PMID:
15019059
33.

Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study.

Tsitsilonis OE, Tsavaris NB, Kosmas C, Gouveris P, Papalambros E.

J Chemother. 2003 Aug;15(4):387-93.

PMID:
12962368
34.

A skeletal muscle troponin T specific ELISA based on the use of an antibody against the soluble troponin T (16-31) fragment.

Tsitsilonis OE, Stoeva S, Echner H, Balafas A, Margomenou L, Katsoulas HL, Troy DJ, Voelter W, Papamichail M, Lymberi P.

J Immunol Methods. 2002 Oct 15;268(2):141-8.

PMID:
12215382
35.

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.

Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M.

Int J Cancer. 2002 Apr 20;98(6):864-72.

36.

Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M.

Eur J Immunol. 2000 Jul;30(7):1957-66.

37.

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M.

J Immunol. 2000 Apr 1;164(7):3902-12.

38.

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.

Baxevanis CN, Spanakos G, Voutsas IF, Gritzapis AD, Tsitsilonis OE, Mamalaki A, Papamichail M.

Cancer Immunol Immunother. 1999 May-Jun;48(2-3):71-84.

PMID:
10414460
39.

Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.

Baxevanis CN, Voutsas IF, Soler MH, Gritzapis AD, Tsitsilonis OE, Stoeva S, Voelter W, Arsenis P, Papamichail M.

Immunopharmacol Immunotoxicol. 1998 Aug;20(3):355-72.

PMID:
9736441
40.

The prognostic value of alpha-thymosins in breast cancer.

Tsitsilonis OE, Bekris E, Voutsas IF, Baxevanis CN, Markopoulos C, Papadopoulou SA, Kontzoglou K, Stoeva S, Gogas J, Voelter W, Papamichail M.

Anticancer Res. 1998 May-Jun;18(3A):1501-8.

PMID:
9673361
41.

Prothymosin alpha: efficient sequence determination by experimental and theoretical capillary electrophoretic support.

Weiler A, Stoeva S, Tsitsilonis OE, Voelter W.

Electrophoresis. 1997 May;18(5):757-61.

PMID:
9194602
42.

Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.

Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M.

Cancer Immunol Immunother. 1995 Jun;40(6):410-8.

PMID:
7543022

Supplemental Content

Loading ...
Support Center